Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes

Cancer

Volumn 119, Issue 23, 2013, Pages 4094-4102

  Okuwaki, Kosuke ^a   Kida, Mitsuhiro ^a   Mikami, Tetuo ^a   Yamauchi, Hiroshi ^a   Imaizumi, Hiroshi ^a   Miyazawa, Shiro ^a   Iwai, Tomohisa ^a   Takezawa, Miyoko ^a   Saegusa, Makoto ^a   Watanabe, Masahiko ^a   Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

2010 World Health Organization classification; neuroendocrine tumor; pancreatic neuroendocrine tumors; somatostatin receptor type 2A; SSTR 2a

Indexed keywords

SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR TYPE 2A; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR INVASION;

2010 WORLD HEALTH ORGANIZATION CLASSIFICATION; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMORS; SOMATOSTATIN RECEPTOR TYPE 2A; SSTR-2A;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES;

EID: 84887995076     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28341     Document Type: Article

References (22)

1. Mizutani G, Nakanishi Y, Watanabe N, et al. Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry. Acta Histochem Cytochem. 2012; 45: 167-176.
2. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000; 95: 3276-3281.
3. di Bartolomeo M, Bajetta E, Buzzoni R,. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by Italian Trials in Medical Oncology Group. Cancer. 1996; 77: 402-408.
4. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G,. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002; 146: 707-716.
5. Sobin LH, Gospodarowicz MK, Wittekind C, eds. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 7th ed. Wiley-Blackwell, Oxford; 2009.
6. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. World Health Organization Classification of Tumours of the Digestive System. Lyon, France: IARC Press; 2010.
7. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007; 20: 1172-1182.
8. Corleto VD, Falconi M, Panzuto F, et al. Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology. 2009; 89: 223-230.
9. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973; 179: 77-79.
10. Moller LN, Stidsen CE, Hartmann B, Holst JJ,. Somatostatin receptors. Biochim Biophys Acta. 2003; 1616: 1-84.
11. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP,. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010; 139: 742-753.
12. Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995; 92: 1580-1584.
13. Janson ET,. Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary. 2006; 9: 249-256.
14. Jann H, Denecke T, Koch M, Pape UF, Wiedenmann B, Pavel M,. Impact of octreotide LAR on tumour growth control as first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology. 2012; 95: 157-176.
15. Schmid HA, Lambertini C, van Vugt HH, et al. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology. 2012; 95: 232-247.
16. Hamilton NA, Liu TC, Cavatiao A, et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery. 2012; 152: 107-113.
17. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010; 45: 234-243.
18. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501-513.
19. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 514-523.
20. Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006; 51: 1033-1038.
21. Terashima T, Morizane C, Hiraoka N, et al. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology. 2012; 96: 324-332.
22. Wildemberg LE, Vieira Neto L, Costa DF, et al. Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry. J Endocrinol Invest. 2012; 35: 580-584.